F S&P 500
5,210.00 -2.75 (-0.05%) F Dow Jones
39,183.00 -12.00 (-0.03%) F Nasdaq
18,166.25 -20.25 (-0.11%) E-mini Russell 2000 Index Futur
2,061.90 -2.90 (-0.14%) Petróleo
79.43 +0.44 (+0.56%) Oro
2,318.50 -3.80 (-0.16%)
LivaNova PLC (LIVN)
Fuera de horario:
LivaNova PLC
20 Eastbourne Terrace
London W2 6LG
United Kingdom
44 20 3325 0660
https://www.livanova.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo: 2,900
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Alex Shvartsburg | Chief Financial Officer | 1.2M | N/D | 1971 |
| Mr. Michael D. Hutchinson | Senior VP, Chief Legal Officer & Company Secretary | 1.09M | N/D | 1971 |
| Ms. Trui Hebbelinck | Chief Human Resources Officer | 895.05k | N/D | 1973 |
| Mr. Vladimir A. Makatsaria | CEO & Director | N/D | N/D | 1973 |
| Mr. Badri Amurthur | Chief Technology Officer | N/D | N/D | N/D |
| Lindsey Little | Senior Director of Investor Relations | N/D | N/D | N/D |
| Deanna Wilke | Vice President of Corporate Communications | N/D | N/D | N/D |
| Mr. Matthew Joseph Dodds III | Senior Vice President of Corporate Development & IT | N/D | N/D | N/D |
| Dr. Bryan D. Olin Ph.D. | Senior VP & Head of Product Development - Neuromodulation | N/D | N/D | 1967 |
| Mr. Ryan Miller | President of Advanced Circulatory Support | N/D | N/D | N/D |
Descripción
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
Gestión corporativa
La calificación ISS Governance QuickScore de LivaNova PLC a partir del 1 de mayo de 2024 es 2. Las puntuaciones principales son Auditoría: 6; Junta: 1; Derechos del accionista: 3; Compensación: 4.
